Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

Zacks Industry Outlook Highlights Verizon, AT&T and Liberty Latin America

View original at finance.yahoo.com
Zacks Industry Outlook Highlights Verizon, AT&T and Liberty Latin America For Immediate Release Chicago, IL – February 13, 2026 – Today, Zacks Equity Research discusses Verizon Communications Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The wireless industry is currently trading at EV/EBITDA of 9.03X compared with the S&P 500's 17.21X and the sector's 19.40X

    80% confidence
  • Liberty Latin America is poised to benefit from an end-to-end communications platform, leveraging the power of a sub-sea network, fixed-line networks and mobile platforms

    80% confidence
  • Aggressive competition is likely to limit telecom operators' ability to attract and retain customers, affecting operating and financial results

    80% confidence
  • The Zacks Wireless National industry carries a Zacks Industry Rank #166, placing it in the bottom 32% of more than 250 Zacks industries

    80% confidence
  • Verizon is likely to retain its lead in promulgating 5G mobile networks nationwide by using virtualized machines, advanced levels of operational automation and adaptability

    80% confidence
  • Verizon appears to be at a critical inflection point and remains focused on making necessary capital expenditures

    80% confidence
  • AT&T is the second largest wireless service provider in North America and one of the world's leading communications service carriers

    80% confidence
  • The top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than two to one

    80% confidence
  • Over the past five years, the wireless industry has traded as high as 9.42X EV/EBITDA, as low as 6.33X and at the median of 7.51X

    80% confidence
  • The Zacks Wireless National industry appears to be plagued by high capital expenditures for infrastructure upgrades, tariff uncertainty, supply-chain disruptions due to the prolonged Russia-Ukraine war, Middle East tensions and high customer inventory levels

    80% confidence
  • The industry is likely to benefit in the long run from a fast-track 5G deployment and extensive fiber densification

    80% confidence
  • Since 2000, Zacks' top stock-picking strategies have produced average gains of +48.4%, +50.2% and +56.7% per year versus S&P's +7.7% average gain per year

    80% confidence
  • AT&T is benefiting from increased fiber convergence with accelerated growth in fiber customers in areas where it has solid wireless services

    80% confidence
  • Verizon, AT&T, and Liberty Latin America are likely to gain from higher demand for scalable infrastructure for sustainable networks with a wide proliferation of IoT, wireless traction and solid broadband momentum

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Zacks Industry Outlook Highlights Verizon, AT&T and Liberty Latin America — Source | Via News | ViaNews Market